Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: 16 week results of a phase 3 randomized, double‐blind, placebo controlled trial in patients with prior inadequate response or intolerance to tumor necrosis factor inhibitors
Deodhar A et al. Arthritis Rheumatol 2018. doi: 10.1002/art.40753
Please follow the link below to view this article in full on a third-party website. Note that a subscription or payment may be required.